Bortezomib (PS-341)

製品コードS1013 別名：LDP-341, MLM341

Bortezomib (PS-341)化学構造

分子量(MW)：384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

サイズ 価格(税別)  
JPY 11620.00
JPY 44820.00
JPY 111220.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(154)

カスタマーフィードバック(25)

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
ターゲット
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外試験

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NVf5RWdJS3m2b4TvfIlkKEG|c3H5 MmfFOVAh|ryP M3LWblQ5KGh? MWjEUXNQ MXTLbYxteyClZXzsd{BjgSCvb4LlJJRp[W5iOUml NUPuPJBMOTB2OUm2OFM>
OVCA 429 M3\ncGZ2dmO2aX;uJGF{e2G7 NIL0Xoc{ODBibl2= MmDoOFghcA>? M3PDW2ROW09? Mnm1SIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz MUCxNFk6QTd4Nh?=
RPMI8226 NVvle4QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXPNVAxKG6P NU\tPJpIPDhiaB?= NYC3eFB3TE2VTx?= NYHqNYVOUUN3ME2zNEBvVQ>? Mmq1NVE{ODZ2OEm=
Dox40 NX\jXFlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmxNFAhdk1? Ml3iOFghcA>? NXjtXVlUTE2VTx?= NVzCUJF5UUN3ME20NEBvVQ>? MkPQNVE{ODZ2OEm=
MR20 MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT5T5I4OTByIH7N NIO5V4M1QCCq MVjEUXNQ M4G5NmlEPTB;MkCgcm0> NWjkXFlSOTF|ME[0PFk>
LR5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1OwblExOCCwTR?= NWXzdotLPDhiaB?= M{XXZmROW09? M2HSdWlEPTB;MkCgcm0> NV73PZNXOTF|ME[0PFk>
U266 M2T6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS4VWF6OTByIH7N MkTtOFghcA>? MnKwSG1UVw>? MkHTTWM2OD1|IH7N NU\xSIR5OTF|ME[0PFk>
IM-9 M3O0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[5Z|ExOCCwTR?= M4jKNlQ5KGh? M1nzNmROW09? M1XJOGlEPTB;NjDuUS=> NX[0cXZ[OTF|ME[0PFk>
Hs Sultan NHnxb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjzOogyODBibl2= NV\uOotoPDhiaB?= NWPBOpRJTE2VTx?= MnexTWM2OD1{MDDuUS=> MX6xNVMxPjR6OR?=
PAM-LY2 NGTjZVlHfW6ldHnvckBCe3OjeR?= NUmxe3I{OTByIH7N MlrCNVIhcA>? NVHxVndiTE2VTx?= Mof5TY5pcWKrdIOgUmYu|rqEIHHjeIl3[XSrb36= NUjMbW5WOTF|NUC5NVM>
PAM 212 NXrvS2pRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;lZ3YyODBibl2= M2foVFczKGh? NW\T[IRYTE2VTx?= NEjYOWhKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MoGyNVE{PTB7MUO=
PAM-LY2 NWTVZpFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3FR5oyODBibl2= M4nIcFczKGh? NEHoVHhFVVOR M{nk[WlvcGmkaYTzJINmdGxidnnhZoltcXS7 NUOyRmVROTF|NUC5NVM>
B4B8 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHT[IQyODBibl2= MY[3NkBp MmfLSG1UVw>? NVr0R3hbUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= M3HtZlEyOzVyOUGz
B7E3 M3r5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTiV5kyODBibl2= NG\oWWY4OiCq NITHclNFVVOR NGr1[|JKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NFr4cFkyOTN3MEmxNy=>
UM-SCC-9 NXjzNm56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHuNVAxKG6P MV:3NkBp M{PWVmROW09? M{TvR2lvcGmkaYTzJINmdGxidnnhZoltcXS7 MWGxNVM2ODlzMx?=
UM-SCC-11B MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7FNVAxKG6P Mo\2O|IhcA>? MlfZSG1UVw>? MlnxTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NEPHOYsyOTN3MEmxNy=>
H460 MVLGeY5kfGmxbjDBd5NigQ>? MXyxNEDPxE1? Mo\NNlQhcA>? Mkf6SG1UVw>? NHq3T4lKdmS3Y3XzJGJkdC1{IIDoc5NxcG:{eXzheIlwdiCjbnSgZ4xm[X[jZ3WgZ49zemWuYYTl[EB4cXSqIFeyMW0heGijc3WgZZJz\XO2 M12zSFEzPDl{MUG3
U266 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\4[|dQPTByIH7nM41t NFKzToI1QCCq NEfLUGlFVVOR MoK3TY5pcWKrdIOgZ4VtdCCpcn;3eIg> NF[3PXAyOjZ|MU[xPS=>
ARH77 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;Le3I2ODBibnevcYw> MUK0PEBp M2rKfmROW09? NUfvdVNUUW6qaXLpeJMh[2WubDDndo94fGh? M4fvNFEzPjNzNkG5
WAD-1 MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILyS|A2ODBibnevcYw> NYrT[2NPPDhiaB?= MoHsSG1UVw>? NV:0S3dlUW6qaXLpeJMh[2WubDDndo94fGh? NWnPS|JrOTJ4M{G2NVk>
U266/LR7 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1qy[VUxOCCwZz;tcC=> MWG0PEBp MV\EUXNQ M1r4PWlvcGmkaYTzJINmdGxiZ4Lve5Rp MYqxNlY{OTZzOR?=
U266/dox4 NHX3VHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfkNJQ2ODBibnevcYw> NYLKWVFIPDhiaB?= MoXLSG1UVw>? NXr3TlJxUW6qaXLpeJMh[2WubDDndo94fGh? MYCxNlY{OTZzOR?=
RPMI8226/LR5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;5fXo2ODBibnevcYw> Mn;rOFghcA>? NXTHPXVUTE2VTx?= MUHJcohq[mm2czDj[YxtKGe{b4f0bC=> M2C5dFEzPjNzNkG5
H460 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PG[|ExKM7:TR?= NWG1OYJ{PzJiaB?= NWrnTIROTE2VTx?= Ml3aTWM2OD1zMECgcm0> Mk\wNVI3OzF4MkC=
H358 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLWblRoOTBizszN NYq2bmZSPzJiaB?= MojySG1UVw>? MX7JR|UxRTdyIH7N MlXINVI3OzF4MkC=
H322 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD0bIRrOTBizszN NF;kO|Y4OiCq MXLEUXNQ MVnJR|UxRTZ{MDDuUS=> M3\UPFEzPjNzNkKw
H460 MnrxSpVv[3Srb36gRZN{[Xl? MYWxNFAhdk1? M2HQUVI1KGh? M2rrWWROW09? M4PHV2lv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl? NHzIZ20yOjZ|MU[yNC=>
LNCap-Pro5 MoO0SpVv[3Srb36gRZN{[Xl? MmLwNUDPxE1? NGLQTmU1KGh? MlPWSG1UVw>? NXLqbVdYW3SjYnnsbZpmeyCyNUO= M3O0cFE1PjF{NUOy
T29 MWrBdI9xfG:|aYOgRZN{[Xl? NH7xfJo2OCCwTR?= M2jFZ|Q5KGhi M1noNmROW09? M4mzVmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NWj6emp7OTZ5N{ixO|k>
T29Kt1 NYO4cGVSSXCxcITvd4l{KEG|c3H5 NVrocYg1PTBibl2= MUe0PEBpKA>? NF74bGJFVVOR M3PDUGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXWxOlc4QDF5OR?=
HCT116 NHvhWFJCeG:ydH;zbZMhSXO|YYm= MonyOVAhdk1? MoTxOFghcCB? MnLkSG1UVw>? MlmyTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M371TFE3Pzd6MUe5
HKe-3 NVfvd41sSXCxcITvd4l{KEG|c3H5 NWLhfJc4PTBibl2= NUTJW|Q5PDhiaDC= NYrNNpZqTE2VTx?= MnjwTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NGm2NWIyPjd5OEG3PS=>
NB-1691 Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHRdXo1OSEQvF2= M4DBPFczKGh? M1;ITmlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?= NV3qcnZ4OTd4OEm2PFQ>
CHLA-255 M1HW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HnUFEh|ryP MXi3NkBp NX;wVIhYUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKl M3vWXlE4Pjh7Nki0
SK-N-AS NHLRUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xJO69VQ>? MoTVO|IhcA>? NFPHOYhKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMUCl MmDHNVc3QDl4OES=
NB-1691 NEjQXHRHfW6ldHnvckBCe3OjeR?= M2LoeVExKG6P MYmyOEBp MYTTbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubIOgbY4hfGinIFewM2cyKHCqYYPl M2j3PVE4Pjh7Nki0
CHLA-255 M2nVNWZ2dmO2aX;uJGF{e2G7 Ml\iNVAhdk1? MkG2NlQhcA>? MnP4UY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V? MUOxO|Y5QTZ6NB?=
RPMI 8226 NX\zW2F{TnWwY4Tpc44hSXO|YYm= NFvUb5gzOCCwTR?= NWe3eYVyQCCq NGHKZZpUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MYixPVQ{PjB3MB?=
MM.1S MmjySpVv[3Srb36gRZN{[Xl? MYGyNEBvVQ>? NH3QT3c5KGh? NXS4V2lqW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MUmxPVQ{PjB3MB?=
U266 MlXhSpVv[3Srb36gRZN{[Xl? Ml3JNlAhdk1? M{HJN|ghcA>? M3\DeHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MX[xPVQ{PjB3MB?=
OPM1 M2jROGZ2dmO2aX;uJGF{e2G7 MWqyNEBvVQ>? M3TDOlghcA>? NEX5[oxUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NInKVVQyQTR|NkC1NC=>
INA6 NUfpSpFFTnWwY4Tpc44hSXO|YYm= M3fVRVIxKG6P NXLWZoVZQCCq Mn\GV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> NITYTG8yQTR|NkC1NC=>
OPM2 MoH6SpVv[3Srb36gRZN{[Xl? M{PudlIxKG6P NX;SRXdRQCCq NGfwelVUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M2HBe|E6PDN4MEWw
RPMI 8226 M2fFVGZ2dmO2aX;uJGF{e2G7 Mn\VNlAhdk1? NWDWO|JQQCCq Ml3xTY5lfWOnczDEUmEhe3mwdHjld4l{ MWCxPVQ{PjB3MB?=
BaF/3 NHPXT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTMTFZXOTByIH7N M4TSdFQ5KGh? NV7zVYV{UUN3ME22MlIhdk1? NGXJPY0zODNyNU[5Ni=>
BaF/3-p210 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP1NVAxKG6P M1PQUVQ5KGh? MknUTWM2OD12Lkegcm0> NXXIU5dlOjB|MEW2PVI>
TCC-S M{jMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu1dFYyODBibl2= M2S2N|Q5KGh? NGDSbGNKSzVyPUKuPEBvVQ>? MnnINlA{ODV4OUK=
BaF/3 MUTGeY5kfGmxbjDBd5NigQ>? M3\oTlYhdk1? NHXP[W81QCCq NED1c2lKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q> NE\q[IgzODNyNU[5Ni=>
BaF/3-p210 M2TjbmZ2dmO2aX;uJGF{e2G7 M3i2WVYhdk1? NEC3[pc1QCCq NYTDSYVTUW6mdXPld{BiKHOuaXfoeEBIOSClZXzsMYN6[2ynIHHydoV{fA>? NEXuUlgzODNyNU[5Ni=>
BaF/3-p210 NVfFXnNyTnWwY4Tpc44hSXO|YYm= Mo\EOkBvVQ>? M1zTdlI1KGh? NVrZcHVUWmWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGGwZDD0bIUh[WO2aY\peJkhd2ZiUnK= MWSyNFMxPTZ7Mh?=
Raji M1nxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rjXFEh|ryP NH:0bFEzPCCq NGrySVdT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MkT6NlEyPzB7OEi=
LCL-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXztcFFpOSEQvF2= MoHnNlQhcA>? M3L6eHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NYDlR2tOOjFzN{C5PFg>
LCL-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOxJO69VQ>? M{OzSlI1KGh? M1;pT3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MUOyNVE4ODl6OB?=
BJAB NInVPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETSb|gyKM7:TR?= M3LBNlI1KGh? NHmzWllT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MU[yNVE4ODl6OB?=
SNT-13 M3\TdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G5SlEh|ryP MkDENlQhcA>? NUTlRm53WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NIG0N4kzOTF5MEm4PC=>
SNT-16 NGXLZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofPNUDPxE1? MV6yOEBp MWHS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MUSyNVE4ODl6OB?=
Jurkat MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmixNUDPxE1? NX\KOmpKOjRiaB?= Mn7MVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MWWyNVE4ODl6OB?=
KAI-3 NF3wPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:0dVEh|ryP MorpNlQhcA>? MW\S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MWCyNVE4ODl6OB?=
SNK-6 NGDCc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DHUlEh|ryP MWKyOEBp NXK5eWJSWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NXq4TXpXOjFzN{C5PFg>
KHYG-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfOPVB{OSEQvF2= Mk\yNlQhcA>? NETzTIlT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M2rSZlIyOTdyOUi4
SNT-16 MX;BdI9xfG:|aYOgRZN{[Xl? MWSxJO69VQ>? NF32TYY3KGh? NWP2dlg{UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MYiyNVE4ODl6OB?=
Jurkat MlvRRZBweHSxc3nzJGF{e2G7 MlXXNUDPxE1? M2G5S|YhcA>? M2DK[Wlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M{S3S|IyOTdyOUi4
KAI-3 M{DWNWFxd3C2b4Ppd{BCe3OjeR?= NH;IeHAyKM7:TR?= MlPEOkBp MX3JcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXeyNVE4ODl6OB?=
KHYG-1 MnX1RZBweHSxc3nzJGF{e2G7 NXrYNnU{OSEQvF2= MX22JIg> MWjJcoR2[2W|IHPlcIwh[XCxcITvd4l{ M4XaN|IyOTdyOUi4
SNT-13 NH\Ob4dCdnSrdnnyZYwhSXO|YYm= MkGwNUDPxE1? MnvONlQhcA>? NV7XfVF{UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY M33VOVIyOTdyOUi4
SNT-16 NXTOUlZqSW62aY\pdoFtKEG|c3H5 MmDxNUDPxE1? MmfRNlQhcA>? M4LwTWlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MUOyNVE4ODl6OB?=
KAI-3 NUTwd416SW62aY\pdoFtKEG|c3H5 M37wNFEh|ryP NYOwTGhsOjRiaB?= M{TRVGlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? Ml6yNlEyPzB7OEi=
SNK-6 NHPYdldCdnSrdnnyZYwhSXO|YYm= MmTmNUDPxE1? M4HKfFI1KGh? MlzjTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX Ml;rNlEyPzB7OEi=
RAW 264.7 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjYNVAxKG6P M4HuOlQ5KGh? MWfS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MY[yNlQzPzF3NB?=
A375 NU\DZms4SXCxcITvd4l{KEG|c3H5 Mo\iNVAhdk1? MmC3NlQhcA>? NHzJb3pKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MonQNlMxPzlyOEO=
BLM Mn:xRZBweHSxc3nzJGF{e2G7 NUHwUHROOTBibl2= MX6yOEBp NF3Ee|NKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NEf2TZgzOzB5OUC4Ny=>
A375 NUW3ZXBiSXW2b4DoZYd6KEG|c3H5 MX:xNEBvVQ>? MXexNkBp NEjVTm9KdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MlL4NlMxPzlyOEO=
BLM MnyyRZV1d3CqYXf5JGF{e2G7 Mm\QNVAhdk1? MmXNNVIhcA>? NEW2WnZKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NWj6fJZVOjNyN{mwPFM>
H1299 MV3BdI9xfG:|aYOgRZN{[Xl? M3nOUVgxKG6P NHTxUVIzPCCq MXLEUXNQ NF3kOY5U\W6|aYTpfoV{KE6VQ1zDJINmdGy|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?= M{PUb|I2OzJ|Nkmz
Hut-78 NFLZeFBHfW6ldHnvckBCe3OjeR?= NHzNR4MyODBibl2= NFmzV48zPCCq NGH0bVFFVVOR NYHieVFkTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMDDlfJBz\XO|aX;u NYHUNXVkOjV4OEGzN|U>
H9 NUXHdFJ2TnWwY4Tpc44hSXO|YYm= MV[xNFAhdk1? M4W3SlI1KGh? MX;EUXNQ NGLMNJJFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFzIHX4dJJme3Orb36= NFi4enAzPTZ6MUOzOS=>
HH MUnGeY5kfGmxbjDBd5NigQ>? MlP6NVAxKG6P NInOdlgzPCCq NX:we|dUTE2VTx?= MYLkc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEzKGW6cILld5Nqd25? NWrPXm96OjV4OEGzN|U>
Hut-78 MnjvUYloemG2aX;uJGF{e2G7 M{LsdVExOCCwTR?= NGH6Z20zPCCq MVLEUXNQ MoXIVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlyJR?= MVGyOVY5OTN|NR?=
HH M3fp[W1q\3KjdHnvckBCe3OjeR?= NXjVTpdDOTByIH7N NYTj[I14OjRiaB?= MXPEUXNQ NGfId4xT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUGl M3LPS|I2PjhzM{O1
U937 Mmf6SpVv[3Srb36gRZN{[Xl? MVWxNFAhdk1? M3\4dFYhcA>? MlW1TY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>? NGTYcW0zPTd7MUS3Oy=>
human PBMC NH\pXmxHfW6ldHnvckBCe3OjeR?= M2LwcFExOCCwTR?= M3HyS|I1KGh? NG\ie|dKdmS3Y3XzJGlNNThicnXs[YF{\Q>? NFXXSI0zPTd7MUS3Oy=>
ES6 NWjnT2xqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMECyNUBvVQ>? NFTmRmtUSU6JRWK=
SK-UT-1 MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnFXlZKSzVyPUCuNVY{KG6P MoXmV2FPT0WU
SH-4 MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\KUXVVUUN3ME2wMlE4OyCwTR?= M1nhUXNCVkeHUh?=
TE-9 NYPGPGgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjIS2F2UUN3ME2wMlE5OiCwTR?= Mmr5V2FPT0WU
A253 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfOfJZKSzVyPUCuNlA5KG6P NE[xZo1USU6JRWK=
no-10 NHnkTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMkGgcm0> NV3aW|Y{W0GQR1XS
MMAC-SF M3jFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMkG2JI5O NYi3V5VrW0GQR1XS
A101D NFP5TXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{eyNGlEPTB;MD6yNlUhdk1? MW\TRW5ITVJ?
NTERA-S-cl-D1 NHyzW|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFywWnNKSzVyPUCuNlQ{KG6P M{TVbnNCVkeHUh?=
8-MG-BA M1\yV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;NSIRQUUN3ME2wMlI2KG6P NV3aWm9jW0GQR1XS
KNS-42 NYHnenJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLzNHlRUUN3ME2wMlI2QCCwTR?= M3fJ[nNCVkeHUh?=
LXF-289 M{T4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfwTWM2OD1yLkK2PUBvVQ>? NGrEcI1USU6JRWK=
OVCAR-4 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\DRWlEPTB;MD6yPFkhdk1? NEi3W45USU6JRWK=
LOUCY MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;HTWM2OD1yLkK5N{BvVQ>? NIHHfVNUSU6JRWK=
BB65-RCC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInFRWZKSzVyPUCuN|A1KG6P NVGwTHR4W0GQR1XS
D-542MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jRdWlEPTB;MD6zNlkhdk1? MVrTRW5ITVJ?
ONS-76 M2rlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmiyTWM2OD1yLkOzJI5O MmT3V2FPT0WU
BB30-HNC MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSzeHY{UUN3ME2wMlM{PSCwTR?= M3HUOnNCVkeHUh?=
KS-1 NXqzXndYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHJdXNKSzVyPUCuN|Qhdk1? MlzyV2FPT0WU
A388 NICzVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnsT4VqUUN3ME2wMlM2PiCwTR?= NGfIeHpUSU6JRWK=
ES8 NUDlfopUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH21WodKSzVyPUCuOEBvVQ>? NXTDd2R{W0GQR1XS
MZ2-MEL NVjPdldNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwNEC3JI5O MmPxV2FPT0WU
HCC2998 M4DWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPjTWM2OD1yLkSxNkBvVQ>? MkPFV2FPT0WU
D-247MG M13MUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGexU3lKSzVyPUCuOFE{KG6P NUHzdFl[W0GQR1XS
ACN NVrjOIF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13VfmlEPTB;MD60NVchdk1? NF7XPFRUSU6JRWK=
LB2518-MEL M17uPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jkWGlEPTB;MD60NlUhdk1? M3HheXNCVkeHUh?=
ES1 NIr0PHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jMOGlEPTB;MD60N{BvVQ>? MVvTRW5ITVJ?
HCE-T MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHRV5JvUUN3ME2wMlQ{QSCwTR?= MoXXV2FPT0WU
OS-RC-2 M3O0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDn[IhJUUN3ME2wMlQ1KG6P NFvl[ZVUSU6JRWK=
MFH-ino MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LHS2lEPTB;MD60OFMhdk1? NGrmfXVUSU6JRWK=
OCUB-M MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33ifWlEPTB;MD60OFchdk1? MknJV2FPT0WU
CP66-MEL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwNEezJI5O M33oW3NCVkeHUh?=
LB771-HNC NHP0UHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;UTWlEPTB;MD60O|Qhdk1? MoP1V2FPT0WU
DSH1 M{nqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHmTWM2OD1yLkS4JI5O MmLkV2FPT0WU
HUTU-80 MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwNUOzJI5O M{TwcXNCVkeHUh?=
CESS MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXWdFFKSzVyPUCuOVM5KG6P MlXuV2FPT0WU
NCI-H747 NHzVbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS3TWM2OD1yLkWzPUBvVQ>? MW\TRW5ITVJ?
HT-144 NWnKSnFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwNUe2JI5O MV3TRW5ITVJ?
COLO-829 NHG3c3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXGTWM2OD1yLk[xOEBvVQ>? M2XyNnNCVkeHUh?=
A4-Fuk MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu0ZZdtUUN3ME2wMlYzOyCwTR?= NWTPSFBxW0GQR1XS
GI-ME-N MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTNTWM2OD1yLk[zOEBvVQ>? MlvSV2FPT0WU
LB831-BLC MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwNkSxJI5O NV60XpVTW0GQR1XS
HOP-62 Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDZNI8{UUN3ME2wMlY1PyCwTR?= NUD4fHFRW0GQR1XS
BB49-HNC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;q[JNKSzVyPUCuOlUzKG6P M2PLcXNCVkeHUh?=
D-336MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf5bINYUUN3ME2wMlY2PyCwTR?= NXyyeGdxW0GQR1XS
TK10 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwNke5JI5O MYPTRW5ITVJ?
Ramos-2G6-4C10 MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwNkmzJI5O M2HiZnNCVkeHUh?=
LB373-MEL-D MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[2TWM2OD1yLkegcm0> MUHTRW5ITVJ?
SF126 M1LucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[zNYhRUUN3ME2wMlcxOSCwTR?= M32xb3NCVkeHUh?=
UACC-257 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDhcXNHUUN3ME2wMlcyKG6P MnKyV2FPT0WU
KINGS-1 NW\OOpl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPESVNKSzVyPUCuO|IzKG6P MUPTRW5ITVJ?
LS-513 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwN{O5JI5O M2K5UnNCVkeHUh?=
GI-1 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXzR5hKSzVyPUCuO|Y1KG6P M4jMPXNCVkeHUh?=
ES7 M3LJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\Vc2lEPTB;MD63OlYhdk1? MUjTRW5ITVJ?
LB2241-RCC NVzYdnI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF31dmpKSzVyPUCuPFA1KG6P Mn3IV2FPT0WU
D-263MG M2n1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfLTWM2OD1yLkiwO{BvVQ>? M4XGdXNCVkeHUh?=
SW684 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf5U49KSzVyPUCuPFIyKG6P M2DYdXNCVkeHUh?=
ML-2 NI\jT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrx[VdnUUN3ME2wMlgzOSCwTR?= NFrYNFhUSU6JRWK=
SK-LMS-1 MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjjc3NuUUN3ME2wMlg2PCCwTR?= MmPzV2FPT0WU
TE-5 NHG4cGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzScI5KSzVyPUCuPFY2KG6P MkTKV2FPT0WU
QIMR-WIL Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknXTWM2OD1yLki4PUBvVQ>? MnzYV2FPT0WU
NCI-H1355 M4n2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLJfFVKSzVyPUCuPFk2KG6P M{DmWXNCVkeHUh?=
SNB75 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrTTWM2OD1yLkmxNkBvVQ>? MWXTRW5ITVJ?
RXF393 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;RV3dMUUN3ME2wMlkyPCCwTR?= Mlv1V2FPT0WU
IST-MEL1 NHXHdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrXTWM2OD1yLkmxO{BvVQ>? MnzjV2FPT0WU
SF268 M1TRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD3d4hKSzVyPUCuPVI{KG6P MnjDV2FPT0WU
KALS-1 NXfvcHpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\yRZlKSzVyPUCuPVI2KG6P Mn3nV2FPT0WU
HC-1 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7sTWM2OD1yLkm3OUBvVQ>? NUPCZ4hkW0GQR1XS
SW872 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS4TWM2OD1yLkm5OkBvVQ>? MWXTRW5ITVJ?
PSN1 MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DzbWlEPTB;MT6wNUBvVQ>? MmS2V2FPT0WU
TE-1 NXn2[pJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\STWM2OD1zLkCzJI5O NILxd25USU6JRWK=
TE-10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[ye2FrUUN3ME2xMlA{KG6P MlHFV2FPT0WU
RKO MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;MRXpKSzVyPUGuNFYhdk1? MXnTRW5ITVJ?
LC-2-ad M3rh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHxe45qUUN3ME2xMlA5KG6P M3XUcnNCVkeHUh?=
SK-MM-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWxeZNKSzVyPUGuNFkhdk1? NHXxR5JUSU6JRWK=
VA-ES-BJ MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[0TWM2OD1zLkC5JI5O Ml3UV2FPT0WU
MZ7-mel NYrDXI1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7kdlR5UUN3ME2xMlA6KG6P M{e1U3NCVkeHUh?=
D-392MG MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O4d2lEPTB;MT6xJI5O MV;TRW5ITVJ?
CCRF-CEM M13M[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTyTWM2OD1zLkGzJI5O NGX2O4lUSU6JRWK=
EM-2 NUjTU41QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fmdmlEPTB;MT6xOkBvVQ>? M1fjSHNCVkeHUh?=
HAL-01 Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonLTWM2OD1zLkG4JI5O M2nhTXNCVkeHUh?=
TE-8 MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFwMUmgcm0> M{L3O3NCVkeHUh?=
NCI-H1882 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv4TWM2OD1zLkKgcm0> M{T4fXNCVkeHUh?=
Daudi NFLTWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwMkKgcm0> M3zle3NCVkeHUh?=
BL-41 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwMkWgcm0> NGfOUpdUSU6JRWK=
SR M{\aO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwMkWgcm0> NYjTOpZUW0GQR1XS
KM12 M1rZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3VTWM2OD1zLkK3JI5O M3HQNnNCVkeHUh?=
K5 M4\yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLETWM2OD1zLkK4JI5O MUHTRW5ITVJ?
A3-KAW M3e0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXORoJKSzVyPUGuNlghdk1? MkPJV2FPT0WU
CMK NYDDdHhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfUTmxKSzVyPUGuNlkhdk1? MofLV2FPT0WU
Calu-6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFwMkmgcm0> MoPtV2FPT0WU
IST-SL2 MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWniZWJxUUN3ME2xMlMyKG6P NWDtfIdJW0GQR1XS
OPM-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwM{Ogcm0> NHnNfnhUSU6JRWK=
DU-4475 M1jseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7NcWZIUUN3ME2xMlM3KG6P MmLlV2FPT0WU
ECC12 NV:xRnBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFwM{egcm0> NUfSfINFW0GQR1XS
L-540 M2nx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvmTWM2OD1zLkO3JI5O MnvXV2FPT0WU
CAS-1 M2DocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vzb2lEPTB;MT6zO{BvVQ>? NGHHZppUSU6JRWK=
PF-382 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13rOGlEPTB;MT60O{BvVQ>? M{TNRXNCVkeHUh?=
LS-411N Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFSxTJJKSzVyPUGuOVMhdk1? MlP6V2FPT0WU
NCI-H69 NVXjSIdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPmN4RKSzVyPUGuOVQhdk1? NFHRT2tUSU6JRWK=
NB12 MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrxVppKSzVyPUGuOVYhdk1? M1Hid3NCVkeHUh?=
HEL MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnUTWM2OD1zLk[xJI5O NXvuUJpwW0GQR1XS
GCIY MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW4TWM2OD1zLk[yJI5O MWrTRW5ITVJ?
EHEB M{joOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u1fWlEPTB;MT62O{BvVQ>? Mn:1V2FPT0WU
TGBC1TKB MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjnTWM2OD1zLkexJI5O NIHDfGZUSU6JRWK=
KURAMOCHI NWPtWZNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\zUGlEPTB;MT63NkBvVQ>? M2KwdXNCVkeHUh?=
U-266 NG\BVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XuRmlEPTB;MT63OkBvVQ>? M3y0U3NCVkeHUh?=
LC4-1 NYT2UFlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HocWlEPTB;MT63PUBvVQ>? NHHHZ|ZUSU6JRWK=
NCI-H2126 NIXEcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHBc2RKSzVyPUGuPEBvVQ>? NI\BeJJUSU6JRWK=
NCI-H1092 MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXw[FZKSzVyPUGuPEBvVQ>? MWXTRW5ITVJ?
GB-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfsTWM2OD1zLkixJI5O MWHTRW5ITVJ?
MV-4-11 NUPEPJRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwOEKgcm0> MYfTRW5ITVJ?
Becker NHHBSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M333bWlEPTB;MT64N{BvVQ>? NV[4[nRMW0GQR1XS
MPP-89 NX;XWnFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfacXdKSzVyPUGuPFkhdk1? MX3TRW5ITVJ?
BE-13 NH3JeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwOUOgcm0> NIHBV21USU6JRWK=
697 M1mxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rCNmlEPTB;MT65PUBvVQ>? MkLpV2FPT0WU
NKM-1 NF\PPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXaTWM2OD1{IH7N NVnK[FIxW0GQR1XS
NB13 M3n6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG3SXJKSzVyPUKgcm0> NYjHdWlmW0GQR1XS
LS-123 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\5TWM2OD1{LkCyJI5O M13xUXNCVkeHUh?=
NB17 NVTq[3NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPsWFU2UUN3ME2yMlA1KG6P NETaV2pUSU6JRWK=
LAN-6 MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3vfnh{UUN3ME2yMlA2KG6P MXnTRW5ITVJ?
EW-24 M3jh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PsfGlEPTB;Mj6wPEBvVQ>? NVvPbZBNW0GQR1XS
NOS-1 NUXDSFl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPaU|ViUUN3ME2yMlEyKG6P NIrQN4ZUSU6JRWK=
BL-70 M373Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjPOVdKSzVyPUKuNVIhdk1? M4mzXHNCVkeHUh?=
GT3TKB NUnZc4pRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;FRmlKSzVyPUKuNVIhdk1? NFn0eYlUSU6JRWK=
HH MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknBTWM2OD1{LkGzJI5O NG\2c4dUSU6JRWK=
KE-37 M{\xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnYc|Q1UUN3ME2yMlE{KG6P NFfBRmVUSU6JRWK=
MOLT-4 NXnnSY9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJwMUOgcm0> NVrI[5IxW0GQR1XS
EKVX M2fSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;FNYh5UUN3ME2yMlE1KG6P NV\wNXo2W0GQR1XS
KGN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwMUWgcm0> M3H0RXNCVkeHUh?=
ES4 MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFeyelJKSzVyPUKuNVYhdk1? NW\zSYJmW0GQR1XS
SJSA-1 NIrVW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJwMkGgcm0> Ml;KV2FPT0WU
KMOE-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f3XmlEPTB;Mj6yN{BvVQ>? M2rIfHNCVkeHUh?=
NB5 M3XpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJwMkegcm0> NGj0S4ZUSU6JRWK=
BC-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPrTWM2OD1{LkOxJI5O MXXTRW5ITVJ?
NB10 M{P1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWwPGlvUUN3ME2yMlMzKG6P NFrvNJJUSU6JRWK=
RPMI-8226 MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XOUmlEPTB;Mj6zOUBvVQ>? NH;EZlBUSU6JRWK=
SCC-3 NX:3S4ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TrbmlEPTB;Mj6zO{BvVQ>? NYezUpdGW0GQR1XS
ARH-77 Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\vemlEPTB;Mj6zPEBvVQ>? NFnr[YhUSU6JRWK=
NCI-H748 NWTXeIpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwM{mgcm0> M1[1U3NCVkeHUh?=
KU812 NWDZTG51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3STWM2OD1{LkSyJI5O MnzSV2FPT0WU
NCI-H64 NVvKbFJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof2TWM2OD1{LkS0JI5O Mny2V2FPT0WU
NB69 NEm3cmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJwNE[gcm0> MnHHV2FPT0WU
KNS-81-FD MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG0TWM2OD1{LkS4JI5O M{TNV3NCVkeHUh?=
LB1047-RCC NXTHUW4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;PTWM2OD1{LkW3JI5O Mk\0V2FPT0WU
EB-3 MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nybGlEPTB;Mj62OkBvVQ>? NV7FR4N6W0GQR1XS
Mo-T MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv2TWM2OD1{Lke0JI5O NEnoSnNUSU6JRWK=
EW-16 NHvWTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jUV2lEPTB;Mj63OUBvVQ>? NVvZUo52W0GQR1XS
CTV-1 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn1W4pKSzVyPUKuPEBvVQ>? MX7TRW5ITVJ?
ETK-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJwOESgcm0> Ml3WV2FPT0WU
C2BBe1 NHezWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrqTWM2OD1{Lki5JI5O M4HrR3NCVkeHUh?=
MOLT-16 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXI[VhqUUN3ME2yMlg6KG6P NILSeVNUSU6JRWK=
SW954 NFPHW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrOPJpKSzVyPUKuPUBvVQ>? MVXTRW5ITVJ?
HT M1\ub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[wTXRtUUN3ME2zMlAzKG6P NWrwdGdmW0GQR1XS
KARPAS-299 NXnRNHk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzTPVNyUUN3ME2zMlA3KG6P M3HJUnNCVkeHUh?=
MONO-MAC-6 NX;mW2NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTNwMTDuUS=> Mly2V2FPT0WU
CGTH-W-1 NIjWfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq1NoZ{UUN3ME2zMlEhdk1? MnzMV2FPT0WU
SK-PN-DW MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rEfmlEPTB;Mz6xOEBvVQ>? NVj6UploW0GQR1XS
CW-2 NVS1NmhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\MTWM2OD1|LkKxJI5O MnfJV2FPT0WU
SK-N-DZ MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTrdnJKSzVyPUOuNlYhdk1? MX3TRW5ITVJ?
NEC8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTNwM{Wgcm0> MnPUV2FPT0WU
LB996-RCC M4\MRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX5TpA1UUN3ME2zMlQhdk1? MYnTRW5ITVJ?
DB NHf3dGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LPdmlEPTB;Mz60NUBvVQ>? MYjTRW5ITVJ?
TE-15 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXTS2p2UUN3ME2zMlQ{KG6P NX\USINwW0GQR1XS
COR-L88 NWnoT5JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjqbYlRUUN3ME2zMlQ4KG6P Mmq4V2FPT0WU
LAMA-84 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTNwNEmgcm0> M{jCW3NCVkeHUh?=
MEG-01 NGr6PZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPGU4s4UUN3ME2zMlQ6KG6P NYjROVRLW0GQR1XS
LOXIMVI NYXhOWE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\pOINKSzVyPUOuOUBvVQ>? NYXOOHBlW0GQR1XS
RPMI-8402 NWX4[GhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\MTWM2OD1|LkWgcm0> M3XDbHNCVkeHUh?=
KARPAS-45 NWe4Z3Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PPSWlEPTB;Mz61OEBvVQ>? NYnRVnZuW0GQR1XS
HCC1187 NY\keI5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTvd5ZoUUN3ME2zMlU1KG6P NF30UI5USU6JRWK=
MZ1-PC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj0TWM2OD1|LkW0JI5O M3uydHNCVkeHUh?=
no-11 NYmw[XRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Ow[2lEPTB;Mz61OUBvVQ>? MXrTRW5ITVJ?
EVSA-T NYWxO3ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljpTWM2OD1|Lk[gcm0> NHHNXVNUSU6JRWK=
DJM-1 NVK1fFU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTNwNkOgcm0> NUPYWHFsW0GQR1XS
COLO-684 MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjMTWM2OD1|Lk[2JI5O Mk\jV2FPT0WU
NMC-G1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNwNkigcm0> MXHTRW5ITVJ?
LC-1F NYHiNXFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3pXIhFUUN3ME2zMlc1KG6P NHWzTodUSU6JRWK=
RL95-2 NGnRdGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFO2TJZKSzVyPUOuO|khdk1? NUDWR|R4W0GQR1XS
COLO-320-HSR NInOV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPiTWM2OD1|LkmyJI5O MmCzV2FPT0WU
RCC10RGB NGW4bIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwOUOgcm0> MVPTRW5ITVJ?
HD-MY-Z NITMcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;qRYdCUUN3ME2zMlk{KG6P MmXxV2FPT0WU
NCI-H2141 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ThOWlEPTB;ND6wOUBvVQ>? M2Ta[HNCVkeHUh?=
K-562 NX;FXpA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi3TWM2OD12LkGyJI5O M4jYWnNCVkeHUh?=
NCI-H1648 NGP4eINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnMTWM2OD12LkGzJI5O NGTuRYpUSU6JRWK=
OMC-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIexSoVKSzVyPUSuNVghdk1? NIfKb|RUSU6JRWK=
LB647-SCLC M4C0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nncWlEPTB;ND6yNkBvVQ>? MoW0V2FPT0WU
TE-12 MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO5Z2xSUUN3ME20MlI2KG6P MXTTRW5ITVJ?
NOMO-1 NWPBcGlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwM{Ogcm0> MWTTRW5ITVJ?
Raji MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XLTWlEPTB;ND60OkBvVQ>? MWfTRW5ITVJ?
NALM-6 MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjkTWM2OD12LkS5JI5O NFry[WFUSU6JRWK=
HL-60 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvvOXRNUUN3ME20MlY4KG6P M1rmUHNCVkeHUh?=
IST-SL1 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnRTWM2OD12Lk[4JI5O MV3TRW5ITVJ?
MHH-PREB-1 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTRwOE[gcm0> MWPTRW5ITVJ?
MHH-NB-11 NHK3VYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjvUoNPUUN3ME20MlkyKG6P M3\ISHNCVkeHUh?=
JiyoyeP-2003 MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXQOm9KSzVyPUWgcm0> NGe2O|RUSU6JRWK=
SBC-1 Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu4SFVKSzVyPUWuNFEhdk1? M3O0[XNCVkeHUh?=
CHP-126 M3i5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXiTWM2OD13LkC2JI5O MkPnV2FPT0WU
LU-139 M3i0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTVwMUOgcm0> NF;nfXlUSU6JRWK=
NCI-SNU-5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHKdFBKSzVyPUWuNVchdk1? NU\OWJgyW0GQR1XS
SW962 NH6xW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTVwMkGgcm0> M2e3d3NCVkeHUh?=
EW-1 NH;xPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3vTWM2OD13LkOxJI5O MmfwV2FPT0WU
NCI-H1417 Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHw[lFvUUN3ME21MlUyKG6P NHLLVVBUSU6JRWK=
LU-65 MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTVwOESgcm0> MXTTRW5ITVJ?
D-502MG M4PXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzTOlhPUUN3ME22MlM4KG6P M{jYTHNCVkeHUh?=
BC-3 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHWUVZqUUN3ME22MlYyKG6P NEHIcFBUSU6JRWK=
GDM-1 M{S5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfNTWM2OD14Lke3JI5O M3XkPXNCVkeHUh?=
NCI-H2196 MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\6TWM2OD14Lkigcm0> NVHHdXdPW0GQR1XS
NB1 NVjlWlRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv5NlkxUUN3ME22Mlg5KG6P MmfZV2FPT0WU
NCI-H345 NFv3XmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXLPI9KSzVyPUeuNkBvVQ>? MULTRW5ITVJ?
SU-DHL-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnWZYtUUUN3ME23MlI1KG6P NHfnWm1USU6JRWK=
JVM-2 MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXDO|dKSzVyPUeuNlghdk1? M3PyfHNCVkeHUh?=
LU-134-A MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTdwM{mgcm0> NHn0d5dUSU6JRWK=
NCI-H1694 NYfIR4RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTdwNUigcm0> NW\sc25TW0GQR1XS
NCI-SNU-16 NUXF[IlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj1WIZ5UUN3ME23MlY2KG6P MXjTRW5ITVJ?
L-363 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fqWGlEPTB;Nz63JI5O MWfTRW5ITVJ?
KG-1 M3jDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrUbWV4UUN3ME23Mlk1KG6P NF\kVoVUSU6JRWK=
MN-60 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzrTWM2OD16LkG0JI5O M4frRXNCVkeHUh?=
NB6 MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHlUVBKSzVyPUiuOFghdk1? NHPDe2dUSU6JRWK=
MLMA M3HRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRThwOEWgcm0> NFm4Vo1USU6JRWK=
ATN-1 NGLpVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETMOVJKSzVyPUiuPFkhdk1? NXH2Z494W0GQR1XS
SK-NEP-1 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvvOHJKSzVyPUmuNFEhdk1? NXPiXpUxW0GQR1XS
DMS-114 MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITueI5KSzVyPUmuOlIhdk1? NVXXNY9PW0GQR1XS
CTB-1 MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLwdYx2UUN3ME25MlY4KG6P MnzTV2FPT0WU
NCI-H2081 MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLvZ3VKSzVyPUGwMlA6KG6P NF\ONZlUSU6JRWK=
ES5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFyLkO4JI5O M2O0dnNCVkeHUh?=
HCC1599 Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT4VYFKSzVyPUGxMlkyKG6P MWTTRW5ITVJ?
NCI-H23 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF{LkGyJI5O Mn35V2FPT0WU
NCI-H1581 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSxTWM2OD1zMj6yPEBvVQ>? NH;ZSlVUSU6JRWK=
JVM-3 M{ntcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\uTWlEPTB;MUKuPVkhdk1? M3HoS3NCVkeHUh?=
NCI-SNU-1 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF|LkG5JI5O NH;CclhUSU6JRWK=
NB7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXDTWM2OD1zNT65NkBvVQ>? NGHBV2VUSU6JRWK=
JAR MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Wyc2lEPTB;MU[uNVMhdk1? MWDTRW5ITVJ?
TGW M1vOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF4LkS4JI5O M1HEZ3NCVkeHUh?=
U-87-MG MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF4Lke2JI5O MlrKV2FPT0WU
NCI-H1436 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF5LkCxJI5O NIjtO3BUSU6JRWK=
GOTO NW\vU3cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjCPI9LUUN3ME2xO{4xPiCwTR?= MVzTRW5ITVJ?
COLO-800 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF5Lk[0JI5O Mm\6V2FPT0WU
MFM-223 NIfwTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnPb3UzUUN3ME2xO{46OSCwTR?= NFfJdo9USU6JRWK=
EW-18 NHXlWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PSWGlEPTB;MUeuPVYhdk1? NYXHeIJzW0GQR1XS
NB14 NXfab5RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF5Lkm4JI5O NWXROYpKW0GQR1XS
EB2 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrETWM2OD1zOD6wPEBvVQ>? MkX5V2FPT0WU
EoL-1- NVnPUFBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\hTWM2OD1zOD6zNUBvVQ>? NEjGSZZUSU6JRWK=
NCCIT M1PndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3pTWM2OD1zOD6zOkBvVQ>? NWLQfolUW0GQR1XS
DG-75 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEezTnFKSzVyPUG4MlYyKG6P MnjPV2FPT0WU
HCC2218 NFfLWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDxTWM2OD1zOT61JI5O M2GxbnNCVkeHUh?=
TE-6 NUfucWEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJyLkC4JI5O M{OxSHNCVkeHUh?=
SF539 MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHJe4YyUUN3ME2yNE43PyCwTR?= Mk[xV2FPT0WU
NCI-H446 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJzLkG4JI5O NWfyR5JZW0GQR1XS
IST-MES1 NUT6[IpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJ{Lke3JI5O NWfzZndrW0GQR1XS
NCI-H82 M1TFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK3TWM2OD1{Mz6wNkBvVQ>? NULiTW1oW0GQR1XS
HCC2157 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rZ[2lEPTB;MkOuNVMhdk1? Ml30V2FPT0WU
EW-12 M2Xadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnziTWM2OD1{Mz6xO{BvVQ>? NGfSOGdUSU6JRWK=
SIMA NWnhXpJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHmTWM2OD1{Mz6zPEBvVQ>? M3fxW3NCVkeHUh?=
DOHH-2 NF:xV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7mfnlKSzVyPUKzMlQ2KG6P MXzTRW5ITVJ?
IM-9 NEDFfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDVVXp4UUN3ME2yN{42PCCwTR?= NYrScJRTW0GQR1XS
EC-GI-10 M{j6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\PTWM2OD1{ND6yN{BvVQ>? MnzjV2FPT0WU
HDLM-2 NHzLbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXRSIRKSzVyPUK0MlU1KG6P NYHQRpo4W0GQR1XS
LS-1034 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojaTWM2OD1{NT63OUBvVQ>? NUPuR2pyW0GQR1XS
REH MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnNZYlyUUN3ME2yOk41OSCwTR?= MUPTRW5ITVJ?
LU-165 NFjuXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn1RVFKSzVyPUK2MlczKG6P MoPxV2FPT0WU
NH-12 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJ5Lk[3JI5O MmnFV2FPT0WU
WSU-NHL NXfuR492T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJ6LkO5JI5O NGnYcm5USU6JRWK=
ECC4 NWCzeJdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJ6Lke5JI5O NFfPPHlUSU6JRWK=
OCI-AML2 NFXLSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ7Lk[5JI5O MlK5V2FPT0WU
EW-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[0PZhKSzVyPUOwMlU6KG6P M1zq[XNCVkeHUh?=
NCI-H526 M3XSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL1[IFKSzVyPUOyMlU1KG6P NF;oSGZUSU6JRWK=
NCI-H719 NIj0T3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrtNHhKSzVyPUO0MlMyKG6P NF\MToJUSU6JRWK=
KARPAS-422 NIH6fXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTN3LkC0JI5O NVLjVGZCW0GQR1XS
SK-MEL-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXOTWM2OD1|NT6xO{BvVQ>? M4LCWHNCVkeHUh?=
ES3 MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfmfXNKSzVyPUO1MlE6KG6P M1[1cnNCVkeHUh?=
UACC-812 MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\rTWM2OD1|NT60OEBvVQ>? NIPF[WNUSU6JRWK=
C8166 NU[ybJpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlqxTWM2OD1|NT63JI5O Mo\zV2FPT0WU
MDA-MB-134-VI M4jjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[3XmpKSzVyPUO1Mlg4KG6P MVPTRW5ITVJ?
D-283MED M4TZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Xm[GlEPTB;M{euO|khdk1? NYLOO4lYW0GQR1XS
SHP-77 NHrXUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XVeGlEPTB;M{iuNFMhdk1? NEnVUXNUSU6JRWK=
NCI-H2227 Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3POV2lEPTB;NECuOFkhdk1? MVHTRW5ITVJ?
SKM-1 NEG2fGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTR{Lk[zJI5O NV3vdWNzW0GQR1XS
L-428 MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTR|Lki2JI5O NVvuepA4W0GQR1XS
RPMI-6666 NGXzOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknBTWM2OD12NT64PUBvVQ>? MXLTRW5ITVJ?
NCI-H716 MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jMR2lEPTB;NEiuPFEhdk1? NIDCW|lUSU6JRWK=
DMS-79 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTVyLkexJI5O MlP0V2FPT0WU
RS4-11 NFrLO|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELi[JRKSzVyPUWwMlg5KG6P NUDPOpB{W0GQR1XS
NCI-H720 M2jTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLYZWh7UUN3ME21NU4yOSCwTR?= NHK3SG1USU6JRWK=
MC-CAR MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTVzLkWyJI5O NFfj[GdUSU6JRWK=
TALL-1 M2WyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf6cmVmUUN3ME21N{46OSCwTR?= M37adnNCVkeHUh?=
NCI-N87 M1nJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fmfmlEPTB;NUSuNVghdk1? NGTuSphUSU6JRWK=
P30-OHK NUj1ZXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXZVYw2UUN3ME21OE43OSCwTR?= NIDHWGFUSU6JRWK=
LP-1 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzSN3RmUUN3ME22NU4zQCCwTR?= MVzTRW5ITVJ?
YT NWn3V|B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonGTWM2OD14MT64JI5O M1HMOXNCVkeHUh?=
MRK-nu-1 M4fmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHYTWM2OD14MT64NkBvVQ>? NWTJOo1qW0GQR1XS
BT-474 NX:yN4JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTZ3IH7N MlXpV2FPT0WU
NCI-H322M MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTZ4LkGxJI5O M33OdnNCVkeHUh?=
NCI-H128 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTd2Lke3JI5O NVfWNlFtW0GQR1XS
KMS-12-PE M3\uXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTd4LkK0JI5O NUXJPI9oW0GQR1XS
KP-N-YS MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor6TWM2OD15Nj63OEBvVQ>? NVz5NGR6W0GQR1XS
ALL-PO MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX22SmRyUUN3ME23O{43PiCwTR?= MYfTRW5ITVJ?
EW-13 NYP0S3NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjadZRKSzVyPUe3Mlc3KG6P NFTiemZUSU6JRWK=
EW-11 NWfWS3M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jMXGlEPTB;N{iuOVIhdk1? NFvWcWVUSU6JRWK=
SK-N-FI M3TBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFziOlNKSzVyPUiwMlIhdk1? M{L0fXNCVkeHUh?=
CAL-148 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRThzLki0JI5O MXvTRW5ITVJ?
RL NF3yZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj0fYI4UUN3ME24Ok4xQSCwTR?= MkLtV2FPT0WU
AM-38 NVnBNG57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvYTndPUUN3ME24PE4xQCCwTR?= M{PhXHNCVkeHUh?=
RH-1 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjj[2dpUUN3ME25PU45PSCwTR?= NGHZ[G5USU6JRWK=
NCI-H1770 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT2TWM2OD1zMEKuOFkhdk1? M2fq[3NCVkeHUh?=
SIG-M5 MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Lp[2lEPTB;MUC1MlA3KG6P NWDUZ5pxW0GQR1XS
GR-ST MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFzMz6zOEBvVQ>? Mk\TV2FPT0WU
ST486 NIXuNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTFzND6wOkBvVQ>? NHraU|RUSU6JRWK=
NCI-H1650 NWLHdnI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDzV45KSzVyPUGxOU4zQSCwTR?= NF7ndGhUSU6JRWK=
MHH-CALL-2 M1LoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWybmJUUUN3ME2xNVUvPyCwTR?= M3m2OnNCVkeHUh?=
BV-173 NUPaTG9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG3ZZdWUUN3ME2xNlIvPzFibl2= NIH2cZpUSU6JRWK=
MC116 NILocnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXw[401UUN3ME2xOFgvQDVibl2= NILyUYNUSU6JRWK=
NCI-H524 M3nZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTF3OT6xJI5O NXTzZ3l7W0GQR1XS
SCLC-21H NVrz[4JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvZbJdKSzVyPUG1PU41OSCwTR?= MYnTRW5ITVJ?
NCI-H1304 M4nZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF4OT6yNUBvVQ>? MULTRW5ITVJ?
NCI-H510A M2nERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfLNoJKSzVyPUG4OU4{PyCwTR?= NIPkRpVUSU6JRWK=
NCI-H209 NGP4O2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF7Nj61NkBvVQ>? NXLT[WdYW0GQR1XS
KM-H2 MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\LZoVqUUN3ME2xPVcvODVibl2= M{fubnNCVkeHUh?=
NCI-H1395 NFz0eopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIewV3VKSzVyPUKxNE4yOyCwTR?= M4i5WnNCVkeHUh?=
NCI-H1155 M1zQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LWNmlEPTB;MkOwMlMzKG6P NHvrW3FUSU6JRWK=
COR-L279 NHu4OZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTFdlRKSzVyPUK1Nk4yPyCwTR?= NVL1WohEW0GQR1XS
NCI-H1299 NWDCcpM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ4MT63NUBvVQ>? M1j2ZXNCVkeHUh?=
EW-22 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ4Mz63OUBvVQ>? MknFV2FPT0WU
SK-MEL-2 NUTXVJJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:1TWM2OD1{OEGuPUBvVQ>? NVfTZYd[W0GQR1XS
KASUMI-1 M{fTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrQTWM2OD1{OEOuNFUhdk1? MkPFV2FPT0WU
NCI-H187 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjsTWM2OD1{OEeuNFghdk1? MVPTRW5ITVJ?
NCI-H2171 NGD2Z4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ6OD65NkBvVQ>? NX3oOlRpW0GQR1XS
LNCaP-Clone-FGC M4PBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJ7NT6yOkBvVQ>? NUTVU21ZW0GQR1XS
NCI-H1522 Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTNyNz6wOUBvVQ>? NFvaZ4pUSU6JRWK=
SCH MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljYTWM2OD1|MkKuNlIhdk1? NFr3W3lUSU6JRWK=
THP-1 NY\LNZM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTN{Mj62JI5O M2TOPXNCVkeHUh?=
SNU-C1 NXfs[XJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPaeFVUUUN3ME2zOlIvODlibl2= NXrtU3p6W0GQR1XS
CA46 M4DC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vzPWlEPTB;M{ezMlY{KG6P M{LnWHNCVkeHUh?=
NCI-H1963 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD0TWM2OD1|OE[uNVkhdk1? NHPpWndUSU6JRWK=
DEL M2La[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXyR|hsUUN3ME2zPVEvOjdibl2= NEHPUY5USU6JRWK=
TUR NX3pe4VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf1SVVKSzVyPUO5Ok43OSCwTR?= NITJcWJUSU6JRWK=
NCI-H226 M4Dafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTRyMz6yN{BvVQ>? M4PtV3NCVkeHUh?=
COLO-668 M4DQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTRyMz61O{BvVQ>? M13VRnNCVkeHUh?=
CPC-N MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXmRnhKSzVyPUSwN{44PyCwTR?= MX\TRW5ITVJ?
NCI-H889 NEXxWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XBOGlEPTB;NE[xMlkzKG6P MXTTRW5ITVJ?
J-RT3-T3-5 NY\5O2JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz6dpBKSzVyPUWzNk42PyCwTR?= Mn7tV2FPT0WU
MSTO-211H NHrtSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\JSWlEPTB;NUe0MlI3KG6P NW\hOIJsW0GQR1XS
SCC-15 M4S2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTZ4Nz60O{BvVQ>? NUXlNWZWW0GQR1XS
SUP-T1 M2jWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTZ6Nj6wOEBvVQ>? NWPuUXJLW0GQR1XS
DMS-153 NXLL[JFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTd2Nj64N{BvVQ>? M{PM[nNCVkeHUh?=
MS-1 M3rkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn4UpJQUUN3ME23OVkvPDJibl2= NXnMRop6W0GQR1XS
TC-YIK NYLFOFlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTd6MT6wNUBvVQ>? Ml7OV2FPT0WU
RPMI-8866 M4HLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjtdGtKSzVyPUGwNFYvOjhizszN MUTTRW5ITVJ?
KY821 NYS0T2RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFew[4hKSzVyPUGwN|YvODRizszN NHXPVG9USU6JRWK=
P31-FUJ MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFzMUKuO|Uh|ryP M3W1[XNCVkeHUh?=
COLO-824 NXPYZXhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rufmlEPTB;MUK2NU44QCEQvF2= MmjMV2FPT0WU
U-698-M MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzEd3pKSzVyPUKyOlIvOTVizszN MojkV2FPT0WU
TE-441-T NH\ZXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS1TWM2OD1{NUKxMlch|ryP NVzBcFBFW0GQR1XS
IMR-5 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3RXpFiUUN3ME2zOFA6NjZ{IN88US=> NILDS21USU6JRWK=
NCI-H1838 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnrRWdKSzVyPUSxPFYvOzJizszN MkLEV2FPT0WU

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
体内試験 The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

お薦めの試験操作（参考用のみ）

キナーゼ試験：

[4]
+ 展開

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
細胞試験：

[5]
+ 展開
  • 細胞株： Human multiple myeloma cells line U266
  • 濃度： ~10 μM
  • 反応時間： 2 days
  • 実験の流れ：

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (参考用のみ)
動物試験：

[3]
+ 展開
  • 動物モデル： Human plasmacytoma xenografts RPMI 8226
  • 製剤： Saline
  • 投薬量： 1 mg/kg
  • 投与方法： i.v. twice weekly for 4 weeks, then once weekly
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。 		5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 384.24
化学式

C19H25BN4O4
CAS No. 179324-69-7
保管 粉
in solvent
別名 LDP-341, MLM341

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03607643 Not yet recruiting Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme Leaf Vertical Inc. January 15 2019 Phase 1|Phase 2
NCT03701321 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) January 25 2019 Phase 1|Phase 2
NCT03729804 Not yet recruiting Multiple Myeloma University of Chicago December 24 2018 Phase 3
NCT03651128 Not yet recruiting Multiple Myeloma Celgene November 30 2018 Phase 3
NCT03737136 Recruiting Antibody-mediated Rejection Shahid Beheshti University of Medical Sciences November 1 2018 Not Applicable
NCT03652064 Not yet recruiting Multiple Myeloma Janssen Research & Development LLC November 26 2018 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答：

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

selleck catalog

Proteasomeシグナル伝達経路

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

相関Proteasome製品

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat (BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • Ixazomib (MLN9708)

    Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

Tags: Bortezomib (PS-341)を買う | Bortezomib (PS-341) ic50 | Bortezomib (PS-341)供給者 | Bortezomib (PS-341)を購入する | Bortezomib (PS-341)費用 | Bortezomib (PS-341)生産者 | オーダーBortezomib (PS-341) | Bortezomib (PS-341)化学構造 | Bortezomib (PS-341)分子量 | Bortezomib (PS-341)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID